OptimizeRx Co. (NASDAQ:OPRX) was the recipient of a large growth in short interest in August. As of August 31st, there was short interest totalling 561,900 shares, a growth of 27.6% from the July 31st total of 440,200 shares. Approximately 4.8% of the shares of the stock are sold short. Based on an average daily trading volume, of 128,300 shares, the days-to-cover ratio is presently 4.4 days.
Shares of NASDAQ OPRX traded down $0.51 during mid-day trading on Friday, hitting $15.66. 74,800 shares of the company’s stock traded hands, compared to its average volume of 85,680. The company’s 50-day moving average is $15.39 and its two-hundred day moving average is $14.34. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.80 and a quick ratio of 6.80. The company has a market capitalization of $228.93 million, a P/E ratio of 313.20, a PEG ratio of 1.81 and a beta of 0.45. OptimizeRx has a 1 year low of $8.92 and a 1 year high of $18.39.
OptimizeRx (NASDAQ:OPRX) last issued its quarterly earnings results on Wednesday, August 7th. The company reported $0.03 EPS for the quarter, meeting the consensus estimate of $0.03. The company had revenue of $7.01 million for the quarter, compared to the consensus estimate of $6.78 million. OptimizeRx had a net margin of 2.27% and a return on equity of 2.89%. Equities analysts anticipate that OptimizeRx will post 0.22 EPS for the current fiscal year.
A number of large investors have recently modified their holdings of OPRX. 1492 Capital Management LLC lifted its position in OptimizeRx by 118.8% during the second quarter. 1492 Capital Management LLC now owns 265,185 shares of the company’s stock valued at $4,296,000 after acquiring an additional 144,006 shares during the last quarter. Park West Asset Management LLC grew its holdings in shares of OptimizeRx by 14.0% in the second quarter. Park West Asset Management LLC now owns 1,088,088 shares of the company’s stock valued at $17,627,000 after purchasing an additional 133,238 shares in the last quarter. Atlantic Trust LLC acquired a new position in shares of OptimizeRx in the second quarter valued at approximately $126,000. Calamos Advisors LLC acquired a new position in shares of OptimizeRx in the second quarter valued at approximately $4,329,000. Finally, Avenir Corp grew its holdings in shares of OptimizeRx by 90.9% in the second quarter. Avenir Corp now owns 224,100 shares of the company’s stock valued at $3,630,000 after purchasing an additional 106,700 shares in the last quarter. Institutional investors own 52.76% of the company’s stock.
Separately, Zacks Investment Research upgraded shares of OptimizeRx from a “hold” rating to a “buy” rating and set a $16.00 target price on the stock in a research report on Wednesday, August 14th.
OptimizeRx Company Profile
OptimizeRx Corporation provides digital health messaging services for pharmaceutical companies to communicate with healthcare providers. The company's cloud-based solutions support patient adherence to medications by providing real-time access to financial assistance, prior authorization, education, and critical clinical information; and network consists of electronic health records platforms, which provide the ambulatory patient market with access to their workflow at the point-of-care.
Featured Story: Why do companies pay special dividends?
Receive News & Ratings for OptimizeRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OptimizeRx and related companies with MarketBeat.com's FREE daily email newsletter.